← brief for 2026-08-26 · Slowing decline

Angiotensin receptor blocker ameliorates the development of tubulointerstitial injury and fibrosis associated with tubular proteinuria observed in subclinical diabetic kidney disease

Key takeaways

This study tested a blood pressure drug called an angiotensin receptor blocker, or ARB, in early diabetic kidney disease. The drug reduced damage and scarring in the kidney's filtering tubes, and cut the amount of protein leaking into the urine. The work was done in animals, not people, so it is a lead and not a treatment result. ARBs are already used in people with kidney disease for related reasons.

Who did this work

Mariana R. Campos (Universidade Federal de Minas Gerais) · Pedro Henrique S. R. Seabra (Universidade Federal de Minas Gerais) · L. Y. P. OLIVEIRA (Universidade Federal de Minas Gerais) · Vitória L. Lacerda (Universidade Federal de Minas Gerais) · Tawanne M. Souza (Universidade Federal de Minas Gerais) · Mariana C. Moraes (Universidade Federal de Minas Gerais) · Letícia Cristine C. dos Santos (Universidade Federal de Minas Gerais) · Paula P. Campos (Universidade Federal de Minas Gerais) · Celso Caruso‐Neves (Universidade Federal do Rio de Janeiro) · Diogo B. Peruchetti (Universidade Federal de Minas Gerais)

Source

Paper · OpenAlex, Kidney disease concept sweep (verified C2778653478) · 2026-08-20
https://doi.org/10.3389/fphar.2026.1871708